Experiencing pain is the greatest contributor to a reduced quality of life in children with
cerebral palsy (CP). The presence of pain is quite common (~ 60%) and increases with age …

Pain and quality of life are closely interrelated in children with cerebral palsy (CCP). Even
though 67% of CCP experience pain, it is overlooked and untreated. In this study, our …

Sixty-seven percent of children with cerebral palsy (CCP) experience pain. Pain is closely
interrelated to diminished quality of life. Despite this, pain is an overlooked and undertreated …

This review aims to determine the analgesic efficacy of botulinum toxin (BTX) for the
management of pain in children with cerebral palsy (CP). During July and August 2020, a …

Objective To test the hypothesis that pain would be reduced after botulinum toxin type A
(Btx/A) treatment for children with cerebral palsy (CP). Method Thirty-four pediatric patients …

BACKGROUND/AIM: To study proportions and characteristics of children treated and un-
treated with Botulinum neurotoxin (BoNT) in a population-based cohort of children with …

Background Children with cerebral palsy (CP) whom are non-ambulant are at risk of
reduced quality of life and poor health status. Severe spasticity leads to discomfort and pain …

Cerebral palsy (CP) is a non-progressive motor dysfunction leading to multiple morbidities,
including spasticity, which can be managed with botulinum toxin injection (BTI). This …

Aim Previous studies have shown the efficacy of botulinum toxin type A (BoNT‐A) in the
management of ambulant individuals with cerebral palsy (CP). There is little evidence on its …

This literature review uses the International Classification of Functioning, Disability and
Health to describe the quality and variety of the studies of botulinum toxin in children with …